HSBC Holdings
GBT

HSBC Holdings’s Global Blood Therapeutics, Inc. GBT Stock Holding History

HSBC Holdings’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-189,723
Closed -$12.9M – 3324
2022
Q3 		$12.9M Buy
+189,723
New +$10.5M 0.02% 737
2022
Q2 		– Sell
-35,431
Closed -$1.23M – 3534
2022
Q1 		$1.23M Sell
35,431
-71,635
-67% -$2.14M ﹤0.01% 1824
2021
Q4 		$3.14M Buy
107,066
+5,593
+6% +$173K ﹤0.01% 1476
2021
Q3 		$2.61M Buy
101,473
+34,410
+51% +$1.01M ﹤0.01% 1423
2021
Q2 		$2.35M Buy
67,063
+26,543
+66% +$1.04M ﹤0.01% 1379
2021
Q1 		$1.66M Sell
40,520
-5,981
-13% -$275K ﹤0.01% 1372
2020
Q4 		$2.01M Buy
46,501
+35,045
+306% +$1.73M ﹤0.01% 1331
2020
Q3 		$632K Buy
11,456
+4,422
+63% +$281K ﹤0.01% 1790
2020
Q2 		$444K Sell
7,034
-52,789
-88% -$3.62M ﹤0.01% 1914
2020
Q1 		$3M Buy
59,823
+53,857
+903% +$3.61M 0.01% 1028
2019
Q4 		$476K Buy
5,966
+89
+2% +$5.27K ﹤0.01% 2249
2019
Q3 		$285K Buy
+5,877
New +$306K ﹤0.01% 2656

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

HSBC Holdings's GBT Position: Q4 2022 in Review

HSBC Holdings sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 189,723 shares — an estimated $12.9M sold.

HSBC Holdings first reported a position in GBT in Q3 2019 and held it in 12 quarters. The position peaked at $12.9M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • HSBC Holdings reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • HSBC Holdings sold 189,723 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $12.9M.
  • HSBC Holdings first reported a position in Global Blood Therapeutics, Inc. in Q3 2019 and held it in 12 quarters.
  • HSBC Holdings's Global Blood Therapeutics, Inc. position peaked at $12.9M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on HSBC Holdings's 13F filing for Q4 2022, filed 14 Feb 2023.